Cholestatic Liver Disease Clinical Trial
Official title:
Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease
To verify the effect of feeding milk powder rich in medium chain fatty acids on improving the nutritional status and disease status of infants with cholestatic liver disease and To evaluate the safety of feeding milk powder rich in medium chain fatty acids in infants with cholestatic liver disease.
This study will include all types of cholestatic liver disease in infants, randomized controlled study of the efficacy and safety of intervention with rich medium chain fatty acid milk powder,To verify the effect of feeding milk powder rich in medium chain fatty acids on improving the nutritional status and disease status of infants with cholestatic liver disease . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04729751 -
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
|
Phase 2 | |
Active, not recruiting |
NCT04787419 -
Probiotics in Pediatric Chronic Cholestasis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05045482 -
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
|
Phase 1 | |
Active, not recruiting |
NCT04168385 -
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study
|
Phase 2 | |
Completed |
NCT01829698 -
Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC
|
Phase 3 |